Dr. Michael Nicholas Papanicolaou, MD

Dr. Papanicolaou practices at Ciano Ambulatory Surgical Facility (Closed) in Thousand Oaks, California.

Dr. Papanicolaou's NPI, 1922038967, was assigned on July 4, 2006. Dr. Papanicolaou graduated from Duke University School Of Medicine in 1985. Dr. Papanicolaou holds California license A43353.

Dr. Papanicolaou's primary practice is Ciano Ambulatory Surgical Facility (Closed), at 2190 N Lynn Rd, Thousand Oaks, CA 91360 in Ventura County. The practice phone is (805) 497-8411.

Dr. Papanicolaou's primary practice is Ciano Ambulatory Surgical Facility (Closed) in Thousand Oaks, California. Dr. Papanicolaou is also affiliated with Los Robles Regional Medical Center. The medical group on file is Heart Center Cardiology Medical Associates. Dmand AI also links Dr. Papanicolaou to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Papanicolaou practices, 3 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Papanicolaou's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Papanicolaou is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Papanicolaou is licensed in California.

Dmand AI lists aneurysm, atrial fibrillation and flutter, cardiomyopathy, cerebrovascular disease, chronic embolism thrombosis, chronic hypertension, coronary artery disease and heart blockage among the conditions Dr. Papanicolaou treats.

CMS data shows 8,157 Medicare services from Dr. Papanicolaou across 27 procedure codes in 2024, for 1,528 Medicare patients. Medicare paid $1,335,146 for them.

CMS counts 1,528 Medicare patients who saw Dr. Papanicolaou in 2024. The largest group is 75 to 84, with 738 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Papanicolaou's median patient age at 77, with 33% women.

In 2024, Dr. Papanicolaou wrote 7,733 Medicare Part D claims for 946 patients. 80% of them were for generic drugs. CMS names the drug for 7,403 of them, across 71 drugs with 11 or more claims each, at $2,293,310 in total drug cost. In 2023, CMS named 7,604 claims across 73 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Papanicolaou for performance year 2024, reported individually. Dr. Papanicolaou accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 16 papers to Dr. Papanicolaou, published from 2018 to 2024. 2024 was the busiest year, with 4. The most frequent topics are Neoplasm Metastasis, Cancer-Associated Fibroblasts and Tumor Microenvironment. Dr. Papanicolaou has published most often in Nat Commun. Dr. Papanicolaou's most frequent co-authors are Elgene Lim, MD, Mark A. Hlatky, MD and Samuel E. Ross, MD.

CMS Open Payments shows 1,799 general payments to Dr. Papanicolaou from 60 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Janssen Pharmaceuticals, Inc paid the most, $58,700.

Dmand AI lists 1 award for Dr. Papanicolaou.

Dr. Papanicolaou graduated from Duke University School Of Medicine in 1985. Dr. Papanicolaou is a member of ACC.

Dr. Papanicolaou is in network with 8 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.